Rotraud Wieser
Overview
Explore the profile of Rotraud Wieser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grandits A, Reinoehl B, Wagner R, Kuess P, Eckert F, Berghoff A, et al.
Mol Oncol
. 2024 Dec;
PMID: 39656562
Oral squamous cell carcinoma (OSCC) is a malignancy associated with high morbidity and mortality, yet treatment options are limited. In addition to genetic alterations, aberrant gene expression contributes to the...
2.
Edtmayer S, Witalisz-Siepracka A, Zdarsky B, Heindl K, Weiss S, Eder T, et al.
Cell Death Dis
. 2024 May;
15(5):369.
PMID: 38806478
Signal transducer and activator of transcription 3 (STAT3) is frequently overexpressed in patients with acute myeloid leukemia (AML). STAT3 exists in two distinct alternatively spliced isoforms, the full-length isoform STAT3α...
3.
Heller G, Fuereder T, Grandits A, Wieser R
Oncol Res
. 2024 Jan;
32(1):1-17.
PMID: 38188682
Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent cancers worldwide. The main risk factors are consumption of tobacco products and alcohol, as well as infection...
4.
Grandits A, Bromberger S, Heller G, Reinoehl B, Tomasich E, Schossleitner K, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35162973
Head and neck squamous cell carcinoma (HNSCC) is a frequent malignancy with a poor prognosis. So far, the EGFR inhibitor cetuximab is the only approved targeted therapy. A deeper understanding...
5.
Grandits A, Wieser R
Exp Hematol
. 2021 May;
99:1-11.
PMID: 34029637
Relapse is associated with therapy resistance and is a major cause of death in acute myeloid leukemia (AML). It is thought to result from the accretion of therapy-refractory leukemic stem...
6.
Grandits A, Nguyen C, Schlerka A, Hackl H, Sill H, Etzler J, et al.
Leukemia
. 2021 Mar;
35(10):2827-2839.
PMID: 33782537
Despite recent approval of targeted drugs for acute myeloid leukemia (AML) therapy, chemotherapy with cytosine arabinoside and anthracyclines remains an important pillar of treatment. Both primary and secondary resistance are...
7.
Nguyen C, Grandits A, Vassiliou G, Staber P, Heller G, Wieser R
Biomedicines
. 2020 Oct;
8(10).
PMID: 32998330
retinoic acid (atRA) has a dramatic impact on the survival of patients with acute promyelocytic leukemia, but its therapeutic value in other types of acute myeloid leukemia (AML) has so...
8.
Nguyen C, Grandits A, Purton L, Sill H, Wieser R
Cell Cycle
. 2020 Sep;
19(20):2573-2588.
PMID: 32900260
Acute myeloid leukemia (AML) is an aggressive, often fatal hematopoietic malignancy. retinoic acid (atRA), one of the first molecularly targeted drugs in oncology, has greatly improved the outcome of a...
9.
Nguyen C, Schlerka A, Grandits A, Koller E, van der Kouwe E, Vassiliou G, et al.
Cancer Res
. 2020 Sep;
80(20):4527-4539.
PMID: 32873636
Overexpression of , which encodes the alpha chain of the IL2 receptor, is associated with chemotherapy resistance and poor outcome in acute myeloid leukemia (AML). The clinical potential of anti-IL2RA...
10.
Chan L, Lung H, Ngan R, Lee A, Tsao S, Lo K, et al.
Int J Mol Sci
. 2020 Aug;
21(15).
PMID: 32752071
The Wnt signaling pathway is one of the major signaling pathways used by cancer stem cells (CSC). Ecotropic Viral Integration Site 1 (EVI1) has recently been shown to regulate oncogenic...